| Identification | Back Directory | [Name]
GS 143 | [CAS]
916232-21-8 | [Synonyms]
GS 143
4-[4-[[5-(2-Fluorophenyl)-2-furanyl]methylene]-4,5-dihydro-5-oxo-3-(phenylmethyl)-1H-pyrazol-1-yl]benzoic acid | [Molecular Formula]
C28H19FN2O4 | [MDL Number]
MFCD30182334 | [MOL File]
916232-21-8.mol | [Molecular Weight]
466.46 |
| Chemical Properties | Back Directory | [Boiling point ]
667.9±65.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMF:25.0(Max Conc. mg/mL);53.59(Max Conc. mM)
DMF:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.43(Max Conc. mM)
DMSO:31.38(Max Conc. mg/mL);67.28(Max Conc. mM) | [form ]
A crystalline solid | [pka]
4.20±0.10(Predicted) | [color ]
Pink to red |
| Hazard Information | Back Directory | [Uses]
4-[4-[[5-(2-Fluorophenyl)-2-furanyl]methylene]-4,5-dihydro-5-oxo-3-(phenylmethyl)-1H-pyrazol-1-yl]-benzoic Acid blocks LPS-induced expression of inflammatory cytokines in human myelomonocytic cells. | [Biological Activity]
Cell permeable: yes''Primary Target
phosphorylated IKBα | [in vivo]
GS143 (16-32 μg/body; intranasal administration; once; BALB/c mice) treatment suppresses antigen-induced NF-κB activation in the lung of sensitized mice. GS143 treatment also inhibits antigen-induced eosinophil and lymphocyte recruitment into the airways and the expression of Th2 cytokines and eotaxin in the airways[1]. | Animal Model: | BALB/c mice (age 7-8weeks) injected with oval-bu-min[1] | | Dosage: | 16 μg/body or 32 μg/body | | Administration: | Intranasal administration; once | | Result: | Suppressed antigen-induced NF-κB activation in the lung of sensitized mice.
|
| [storage]
Store at +4°C |
|
| Company Name: |
Struchem Co., Ltd.
|
| Tel: |
0512-0512-63009836 15365350169 |
| Website: |
http://www.struchem.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList927327/0.htm |
|